Lessons from TGN1412 and TARGET: Implications for observational studies and meta-analysis

Stephen Senn*

*Corresponding author for this work

Research output: Contribution to journalArticleResearchpeer-review

15 Citations (Scopus)

Abstract

Two very different studies are examined: the first, a very large trial in osteoarthritis (the so-called TARGET study) and the second a very small 'first-in-man' study of the monoclonal antibody TGN1412. In each trial the unbiased estimate of the treatment effect is not efficient and in consequence the efficient estimate is not unbiased. In the case of the large trial it seems reasonable that unbiased estimation is desirable but in the case of the small trial it leads to absurd conclusions. These two cases are examined in detail and some general lessons for the analysis of clinical trials and observational studies and collections of studies are drawn.

Original languageEnglish
Pages (from-to)294-301
Number of pages8
JournalPharmaceutical Statistics
Volume7
Issue number4
DOIs
Publication statusPublished - Oct 2008
Externally publishedYes

Keywords

  • Bias
  • Concurrent control
  • Mean-square error
  • Variance
  • Veiled trial

Fingerprint

Dive into the research topics of 'Lessons from TGN1412 and TARGET: Implications for observational studies and meta-analysis'. Together they form a unique fingerprint.

Cite this